Sorafenib-associated psoriasiform skin changes.
Laquer
Vivian
V
Saedi
Nazanin
N
Dann
Frank
F
Kelly
Kristen
K
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D006225:Hand; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011565:Psoriasis / Q000139:chemically induced / Q000175:diagnosis / Q000473:pathology; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib